- Home
- ZUMZ vs DMAC Comparison
ZUMZ vs DMAC Comparison
Compare ZUMZ & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZUMZ
- DMAC
- Stock Information
- Founded
- ZUMZ 1978
- DMAC 2000
- Country
- ZUMZ United States
- DMAC United States
- Employees
- ZUMZ N/A
- DMAC N/A
- Industry
- ZUMZ Clothing/Shoe/Accessory Stores
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- ZUMZ Consumer Discretionary
- DMAC Health Care
- Exchange
- ZUMZ Nasdaq
- DMAC Nasdaq
- Market Cap
- ZUMZ 211.6M
- DMAC 178.0M
- IPO Year
- ZUMZ 2005
- DMAC N/A
- Fundamental
- Price
- ZUMZ $13.44
- DMAC $3.63
- Analyst Decision
- ZUMZ Hold
- DMAC Strong Buy
- Analyst Count
- ZUMZ 1
- DMAC 2
- Target Price
- ZUMZ $25.00
- DMAC $8.00
- AVG Volume (30 Days)
- ZUMZ 261.3K
- DMAC 325.9K
- Earning Date
- ZUMZ 09-04-2025
- DMAC 08-06-2025
- Dividend Yield
- ZUMZ N/A
- DMAC N/A
- EPS Growth
- ZUMZ N/A
- DMAC N/A
- EPS
- ZUMZ 0.04
- DMAC N/A
- Revenue
- ZUMZ $896,157,000.00
- DMAC N/A
- Revenue This Year
- ZUMZ $3.31
- DMAC N/A
- Revenue Next Year
- ZUMZ $1.34
- DMAC N/A
- P/E Ratio
- ZUMZ $345.43
- DMAC N/A
- Revenue Growth
- ZUMZ 3.01
- DMAC N/A
- 52 Week Low
- ZUMZ $11.31
- DMAC $2.98
- 52 Week High
- ZUMZ $31.37
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- ZUMZ 52.63
- DMAC 44.55
- Support Level
- ZUMZ $13.57
- DMAC $3.48
- Resistance Level
- ZUMZ $14.38
- DMAC $3.88
- Average True Range (ATR)
- ZUMZ 0.63
- DMAC 0.26
- MACD
- ZUMZ 0.04
- DMAC 0.00
- Stochastic Oscillator
- ZUMZ 48.36
- DMAC 30.10
About ZUMZ Zumiez Inc.
Zumiez Inc is a United-States-based specialty retailer engaged in the sale of apparel, footwear, accessories, and hard goods. The company provides merchandise with cultural elements coming from fashion, music, art from action sports, streetwear, and other lifestyles. The company operates under the brands Zumiez, Fast Times, and Blue Tomato, and through both physical stores and websites. The majority of the company's stores are located in the U.S., with the rest in Canada, Australia, and Europe. The U.S. market contributes to the majority of the company's revenue.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.